Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.

ABSTRACT: Gliomas are extremely aggressive brain tumors with a very poor prognosis. One of the more promising strategies for the treatment of human gliomas is targeted immunotherapy where antigens that are unique to the tumors are exploited to generate vaccines. The approach, however, is complicated by the fact that human gliomas escape immune surveillance by creating an immune suppressed microenvironment. In order to oppose the glioma imposed immune suppression, molecules and pathways involved in immune cell maturation, expansion, and migration are under intensive clinical investigation as adjuvant therapy. Toll-like receptors (TLRs) mediate many of these functions in immune cell types, and TLR agonists, thus, are currently primary candidate molecules to be used as important adjuvants in a variety

SUBMITTER: Deng S 

PROVIDER: S-EPMC4259890 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature